Evaluation of the European Society of Cardiology Risk Assessment Score in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
Zoe R BrownDylan HansenWendy StevensNava FerdowsiLaura J RossAlannah QuinlivanJoanne SahharGene-Siew NgianDiane ApostolopoulosJennifer G WalkerSusanna ProudmanGim Gee TengAndrea H L LowKathleen MorrisroeMandana NikpourPublished in: Arthritis care & research (2024)
The 2022 ESC risk assessment strategy applied at baseline and follow-up predicts survival in SSc-PAH. Treatment decisions for SSc-PAH should include risk assessments, aiming to achieve low-risk status according to the 2022 ESC guidelines.
Keyphrases
- systemic sclerosis
- pulmonary arterial hypertension
- risk assessment
- interstitial lung disease
- pulmonary artery
- pulmonary hypertension
- human health
- heavy metals
- cardiovascular disease
- polycyclic aromatic hydrocarbons
- type diabetes
- clinical practice
- climate change
- smoking cessation
- replacement therapy
- idiopathic pulmonary fibrosis
- combination therapy
- thoracic surgery